Moloney Securities Asset Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $813K | Buy |
18,027
+2,011
| +13% | +$93.9K | 0.1% | 214 |
|
|
2025
Q2 | $741K | Sell |
16,016
-17
| -0.1% | -$834 | 0.09% | 220 |
|
|
2025
Q1 | $978K | Buy |
16,033
+258
| +2% | +$15K | 0.13% | 178 |
|
|
2024
Q4 | $892K | Sell |
15,775
-509
| -3% | -$28.4K | 0.12% | 192 |
|
|
2024
Q3 | $843K | Sell |
16,284
-5,400
| -25% | -$253K | 0.11% | 214 |
|
|
2024
Q2 | $901K | Sell |
21,684
-2,757
| -11% | -$123K | 0.13% | 182 |
|
|
2024
Q1 | $1.33M | Sell |
24,441
-3,705
| -13% | -$189K | 0.2% | 130 |
|
|
2023
Q4 | $1.44M | Buy |
28,146
+291
| +1% | +$15.3K | 0.23% | 108 |
|
|
2023
Q3 | $1.62M | Sell |
27,855
-1,664
| -6% | -$102K | 0.29% | 81 |
|
|
2023
Q2 | $1.89M | Sell |
29,519
-1,027
| -3% | -$68.9K | 0.33% | 70 |
|
|
2023
Q1 | $2.12M | Sell |
30,546
-660
| -2% | -$46.6K | 0.39% | 66 |
|
|
2022
Q4 | $2.25M | Sell |
31,206
-9,197
| -23% | -$693K | 0.5% | 51 |
|
|
2022
Q3 | $2.87M | Sell |
40,403
-552
| -1% | -$40K | 0.7% | 36 |
|
|
2022
Q2 | $3.15M | Buy |
40,955
+9,308
| +29% | +$709K | 0.74% | 31 |
|
|
2022
Q1 | $2.31M | Buy |
31,647
+1,040
| +3% | +$69.8K | 0.45% | 63 |
|
|
2021
Q4 | $1.91M | Sell |
30,607
-2,310
| -7% | -$136K | 0.32% | 75 |
|
|
2021
Q3 | $1.95M | Sell |
32,917
-7,591
| -19% | -$500K | 0.35% | 86 |
|
|
2021
Q2 | $2.71M | Sell |
40,508
-6,038
| -13% | -$394K | 0.49% | 61 |
|
|
2021
Q1 | $2.94M | Buy |
46,546
+15,740
| +51% | +$979K | 0.58% | 50 |
|
|
2020
Q4 | $1.91M | Sell |
30,806
-4,802
| -13% | -$295K | 0.42% | 68 |
|
|
2020
Q3 | $2.15M | Buy |
35,608
+10,234
| +40% | +$616K | 0.57% | 52 |
|
|
2020
Q2 | $1.49M | Buy |
25,374
+227
| +0.9% | +$13.6K | 0.43% | 79 |
|
|
2020
Q1 | $1.4M | Buy |
25,147
+8
| +0% | +$489 | 0.5% | 69 |
|
|
2019
Q4 | $1.61M | Buy |
25,139
+4,656
| +23% | +$267K | 0.5% | 49 |
|
|
2019
Q3 | $1.04M | Sell |
20,483
-4,652
| -19% | -$219K | 0.35% | 91 |
|
|
2019
Q2 | $1.14M | Sell |
25,135
-646
| -3% | -$30.1K | 0.38% | 77 |
|
|
2019
Q1 | $1.23M | Buy |
25,781
+3,720
| +17% | +$185K | 0.43% | 57 |
|
|
2018
Q4 | $1.15M | Sell |
22,061
-2,406
| -10% | -$129K | 0.47% | 60 |
|
|
2018
Q3 | $1.52M | Sell |
24,467
-1,946
| -7% | -$115K | 0.53% | 49 |
|
|
2018
Q2 | $1.46M | Sell |
26,413
-9,698
| -27% | -$524K | 0.55% | 47 |
|
|
2018
Q1 | $2.28M | Sell |
36,111
-453
| -1% | -$29.1K | 0.92% | 22 |
|
|
2017
Q4 | $2.24M | Sell |
36,564
-1,809
| -5% | -$113K | 0.94% | 23 |
|
|
2017
Q3 | $2.45M | Buy |
38,373
+5,730
| +18% | +$335K | 1.09% | 19 |
|
|
2017
Q2 | $1.82M | Buy |
32,643
+545
| +2% | +$29.7K | 0.91% | 25 |
|
|
2017
Q1 | $1.75M | Buy |
32,098
+2,384
| +8% | +$131K | 0.9% | 25 |
|
|
2016
Q4 | $1.74M | Buy |
+29,714
| New | +$1.62M | 1.05% | 20 |
|
Other funds holding BMY
Moloney Securities Asset Management's BMY Position: Q3 2025 in Review
Moloney Securities Asset Management increased its Bristol-Myers Squibb (BMY) stake by 13% in Q3 2025, buying an estimated $93.9K and bringing the position to 18,027 shares worth $813K. The position accounts for 0.1% of the portfolio, ranked #214.
Moloney Securities Asset Management first reported a position in BMY in Q4 2016 and has held it in 36 quarters since. The position peaked at $3.15M in Q2 2022. 2,267 funds tracked by Wall St. Rank hold BMY as of Q3 2025.
- Moloney Securities Asset Management held 18,027 shares of Bristol-Myers Squibb worth $813K as of Q3 2025.
- Moloney Securities Asset Management bought 2,011 Bristol-Myers Squibb shares in Q3 2025, an estimated $93.9K.
- Bristol-Myers Squibb made up 0.1% of Moloney Securities Asset Management's portfolio in Q3 2025, its #214 holding.
- Moloney Securities Asset Management first reported a position in Bristol-Myers Squibb in Q4 2016 and has held it in 36 quarters since.
- Moloney Securities Asset Management's Bristol-Myers Squibb position peaked at $3.15M in Q2 2022.
- 2,267 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2025.
Based on Moloney Securities Asset Management's 13F filing for Q3 2025, filed 5 Nov 2025.